Combined renin inhibition/(Pro)renin receptor blockade in diabetic retinopathy- a study in transgenic (mREN2)27 rats

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Batenburg, Wendy W ^a   Verma, Amrisha ^b   Wang, Yunyang ^b   Zhu, Ping ^b   Van Den Heuvel, Mieke ^a   Van Veghel, Richard ^a   Danser, A H Jan ^a   Li, Qiuhong ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN II; HANDLE REGION PEPTIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; LOSARTAN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PRORENIN RECEPTOR; RECEPTOR BLOCKING AGENT; RENIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; AMIDE; AUTACOID; CELL SURFACE RECEPTOR; CYTOKINE; FUMARIC ACID DERIVATIVE; HANDLE-REGION PEPTIDE, RAT; OLIGOPEPTIDE; REN2 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME INHIBITION; GENE EXPRESSION; GLIOSIS; ICAM1 GENE; IN VITRO STUDY; MCP 1 GENE; MUELLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OSMOTIC MINIPUMP; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TNF ALPHA GENE; TRANSGENIC RAT; VEGF GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY; RETINA GANGLION CELL; TRANSGENIC MOUSE;

AMIDES; ANIMALS; APOPTOSIS; BLOOD PRESSURE; CYTOKINES; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; FUMARATES; GLIOSIS; INFLAMMATION MEDIATORS; MICE, TRANSGENIC; OLIGOPEPTIDES; RATS; RECEPTORS, CELL SURFACE; RENIN; RETINAL GANGLION CELLS;

EID: 84903398939     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100954     Document Type: Article

References (67)

1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, et al. (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35: 556-564.
2. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, et al. (2004) Retinopathy in diabetes. Diabetes Care 27 Suppl 1: S84-87. (Pubitemid 38197476)
3. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, et al. (2004) Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye 18: 963-983. (Pubitemid 39430033)
4. Ola MS, Nawaz MI, Siddiquei MM, Al-Amro S, Abu El-Asrar AM (2012) Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. J Diabetes Complications 26: 56-64.
5. Cohn JN (2010) Role of the renin-angiotensin system in cardiovascular disease. Cardiovasc Drugs Ther 24: 341-344.
6. Ghattas A, Lip PL, Lip GY (2011) Renin-angiotensin blockade in diabetic retinopathy. Int J Clin Pract 65: 113-116.
7. Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL (2010) The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res: 1-28.
8. Hanes DS, Nahar A, Weir MR (2004) The tissue renin-angiotensin- aldosterone system in diabetes mellitus. Curr Hypertens Rep 6: 98-105. (Pubitemid 39359549)
9. Luetscher JA, Kraemer FB, Wilson DM (1989) Prorenin and vascular complications of diabetes. Am J Hypertens 2: 382-386. (Pubitemid 19129833)
10. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M (1985) Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 312: 1412-1417. (Pubitemid 15083658)
11. Danser AH, van den Dorpel MA, Deinum J, Derkx FH, Franken AA, et al. (1989) Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 68: 160-167. (Pubitemid 19028740)
12. Franken AA, Derkx FH, Schalekamp MA, Man in t'Veld AJ, Hop WC, et al. (1988) Association of high plasma prorenin with diabetic retinopathy. J Hypertens Suppl 6: S461-463.
13. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, et al. (2002) Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427. (Pubitemid 34596167)
14. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, et al. (2006) Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 69: 105-113. (Pubitemid 43117745)
15. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, et al. (2004) Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 114: 1128-1135. (Pubitemid 39578702)
16. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, et al. (2006) Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 17: 1950-1961. (Pubitemid 44036179)
17. Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, et al. (2003) Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem 278: 22217-22222. (Pubitemid 36830267)
18. Satofuka S, Ichihara A, Nagai N, Koto T, Shinoda H, et al. (2007) Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest Ophthalmol Vis Sci 48: 422-429. (Pubitemid 47251433)
19. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, et al. (2009) (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 58: 1625-1633.
20. Satofuka S, Ichihara A, Nagai N, Yamashiro K, Koto T, et al. (2006) Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci 47: 2686-2692.
21. Wilkinson-Berka JL, Heine R, Tan G, Cooper ME, Hatzopoulos KM, et al. (2010) RILLKKMPSV influences the vasculature, neurons and glia, and (pro)renin receptor expression in the retina. Hypertension 55: 1454-1460.
22. Jadhav M, Yeola C, Zope G, Nabar A (2012) Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development. J Postgrad Med 58: 32-38.
23. Gradman AH, Kad R (2008) Renin inhibition in hypertension. J Am Coll Cardiol 51: 519-528.
24. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, et al. (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46: 569-576. (Pubitemid 41376839)
25. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE (2007) Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50: 2398-2404. (Pubitemid 47512400)
26. Whaley-Connell A, Habibi J, Rehmer N, Ardhanari S, Hayden MR, et al. (2013) Renin Inhibition and ATR blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. Metabolism 62: 861-872.
27. Chou CL, Pang CY, Lee TJ, Fang TC (2013) Direct renin inhibitor prevents and ameliorates insulin resistance, aortic endothelial dysfunction and vascular remodeling in fructose-fed hypertensive rats. Hypertens Res 36: 123-128.
28. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, et al. (2008) Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 51: 1306-1311. (Pubitemid 351555942)
29. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, et al. (2008) Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 118: 984-993. (Pubitemid 351364606)
30. Biswas KB, Nabi AH, Arai Y, Nakagawa T, Ebihara A, et al. (2010) Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro. Hypertens Res 33: 1053-1059.
31. Batenburg WW, Danser AJ (2008) Prorenin and the (pro)renin receptor: binding kinetics, signalling and interaction with aliskiren. J Renin Angiotensin Aldosterone Syst 9: 181-184.
32. Batenburg WW, de Bruin RJ, van Gool JM, Muller DN, Bader M, et al. (2008) Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 28: 1151-1157.
33. Ferri N, Greco CM, Maiocchi G, Corsini A (2011) Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells. J Renin Angiotensin Aldosterone Syst 12: 469-474.
34. Sakoda M, Ichihara A, Kurauchi-Mito A, Narita T, Kinouchi K, et al. (2010) Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. Am J Hypertens 23: 575-580.
35. van Esch JH, van Veghel R, Garrelds IM, Leijten F, Bouhuizen AM, et al. (2011) Handle region peptide counteracts the beneficial effects of the Renin inhibitor aliskiren in spontaneously hypertensive rats. Hypertension 57: 852-858.
36. Batenburg WW, van den Heuvel M, van Esch JH, van Veghel R, Garrelds IM, et al. (2013) The (pro)renin receptor blocker handle region peptide upregulates endothelium-derived contractile factors in aliskiren-treated diabetic transgenic (mREN2)27 rats. J Hypertens 31: 292-302.
37. Lee MA, Bohm M, Paul M, Bader M, Ganten U, et al. (1996) Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol 270: E919-929. (Pubitemid 26298572)
38. Campbell DJ, Rong P, Kladis A, Rees B, Ganten D, et al. (1995) Angiotensin and bradykinin peptides in the TGR(mRen-2)27 rat. Hypertension 25: 1014-1020.
39. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, et al. (2008) Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52: 130-136.
40. Mullins JJ, Peters J, Ganten D (1990) Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344: 541-544.
41. Moravski CJ, Skinner SL, Stubbs AJ, Sarlos S, Kelly DJ, et al. (2003) The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol 162: 151-160. (Pubitemid 36041997)
42. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL (1998) A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 54: 343-352.
43. van Esch JH, Moltzer E, van Veghel R, Garrelds IM, Leijten F, et al. (2010) Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens 28: 2145-2155.
44. Li Q, Verma A, Han PY, Nakagawa T, Johnson RJ, et al. (2010) Diabetic eNOS-knockout mice develop accelerated retinopathy. Invest Ophthalmol Vis Sci 51: 5240-5246.
45. Limb GA, Salt TE, Munro PM, Moss SE, Khaw PT (2002) In vitro characterization of a spontaneously immortalized human Muller cell line (MIO-M1). Invest Ophthalmol Vis Sci 43: 864-869. (Pubitemid 34184508)
46. Lanz TV, Ding ZQ, Ho PP, Luo JA, Agrawal AN, et al. (2010) Angiotensin II sustains brain inflammation in mice via TGF-beta. Journal of Clinical Investigation 120: 2782-2794.
47. Te Riet L, van den Heuvel M, Peutz-Kootstra CJ, van Esch JH, van Veghel R, et al. (2014) Deterioration of kidney function by the (pro)renin receptor blocker handle region peptide in aliskiren-treated diabetic transgenic (mRen2)27 rats. Am J Physiol Renal Physiol 306: F1179-1189.
48. Bringmann A, Wiedemann P (2012) Muller glial cells in retinal disease. Ophthalmologica 227: 1-19.
49. Reichenbach A, Bringmann A (2013) New functions of Muller cells. Glia 61: 651-678.
50. Kumar A, Pandey RK, Miller LJ, Singh PK, Kanwar M (2013) Muller glia in retinal innate immunity: a perspective on their roles in endophthalmitis. Crit Rev Immunol 33: 119-135.
51. Wilkinson-Berka JL, Agrotis A, Deliyanti D (2012) The retinal renin-angiotensin system: roles of angiotensin II and aldosterone. Peptides 36: 142-150.
52. Berka JL, Stubbs AJ, Wang DZ, DiNicolantonio R, Alcorn D, et al. (1995) Renin-containing Muller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci 36: 1450-1458.
53. Wilkinson-Berka JL, Miller AG, Fletcher EL (2010) Prorenin and the (pro)renin receptor: do they have a pathogenic role in the retina? Front Biosci (Elite Ed) 2: 1054-1064.
54. Yokota H, Takamiya A, Nagaoka T, Hikichi T, Ishida Y, et al. (2008) Role of prorenin in the pathogenesis of retinal neovascularization. Hokkaido Igaku Zasshi 83: 159-165.
55. Zubcevic J, Jun JY, Lamont G, Murca TM, Shi P, et al. (2013) Nucleus of the solitary tract (pro)renin receptor-mediated antihypertensive effect involves nuclear factor-kappaB-cytokine signaling in the spontaneously hypertensive rat. Hypertension 61: 622-627.
56. Wilkinson-Berka JL, Tan G, Binger KJ, Sutton L, McMaster K, et al. (2011) Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat. Diabetologia 54: 2724-2735.
57. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, et al. (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102: 783-791. (Pubitemid 28399611)
58. Batenburg WW, Lu X, Leijten F, Maschke U, Muller DN, et al. (2011) Reninand prorenin-induced effects in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor: does (pro)renin-(pro)renin receptor interaction actually occur? Hypertension 58: 1111-1119.
59. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, et al. (2007) Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 25: 2441-2453. (Pubitemid 350060383)
60. Lu X, Garrelds IM, Wagner CA, Danser AH, Meima ME (2013) (Pro)renin Receptor is Required for Prorenin-Dependent and -Independent Regulation of Vacuolar H+-ATPase Activity in MDCK.C11 Collecting Duct Cells. Am J Physiol Renal Physiol.
61. Muller DN, Klanke B, Feldt S, Cordasic N, Hartner A, et al. (2008) (Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 51: 676-681. (Pubitemid 351301520)
62. Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, et al. (1994) Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 35: 1008-1018. (Pubitemid 24079832)
63. Deinum J, Derkx FH, Danser AH, Schalekamp MA (1990) Identification and quantification of renin and prorenin in the bovine eye. Endocrinology 126: 1673-1682. (Pubitemid 20095779)
64. Franken AA, Derkx FH, Blankestijn PJ, Janssen JA, Mannesse CK, et al. (1992) Plasma prorenin as an early marker of microvascular disease in patients with diabetes mellitus. Diabete Metab 18: 137-143.
65. Ludwig J, Kerscher S, Brandt U, Pfeiffer K, Getlawi F, et al. (1998) Identification and characterization of a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-ATPase from chromaffin granules. J Biol Chem 273: 10939-10947. (Pubitemid 28204933)
66. Nishi T, Forgac M (2002) The vacuolar (H+)-ATPases-nature's most versatile proton pumps. Nat Rev Mol Cell Biol 3: 94-103.
67. Adams DS, Robinson KR, Fukumoto T, Yuan S, Albertson RC, et al. (2006) Early, H+-V-ATPase-dependent proton flux is necessary for consistent left-right patterning of non-mammalian vertebrates. Development 133: 1657-1671. (Pubitemid 43810973)